STOCK TITAN

Cronos Group Launches Premium Lord Jones® Brand in Israel, Advancing Borderless Product Strategy

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Cronos Group (NASDAQ: CRON) launched its premium Lord Jones cannabis brand in Israel on February 2, 2026, introducing five indoor-grown flower strains to the Israeli medical market.

The rollout emphasizes small-batch indoor cultivation, cold-cure processing, hand trimming and glass jar packaging, and will expand with special editions and limited-run products.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction

%
1 alert
% News Effect

On the day this news was published, CRON declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Initial flower strains: 5 strains
1 metrics
Initial flower strains 5 strains First phase of Lord Jones launch in Israel

Market Reality Check

Price: $2.66 Vol: Volume of 1,733,536 vs. 2...
normal vol
$2.66 Last Close
Volume Volume of 1,733,536 vs. 20-day average 1,464,881 (relative volume 1.18) indicates elevated trading interest ahead of this news. normal
Technical Shares at $2.51 are trading above the 200-day moving average of $2.35, despite a -3.09% move over the last 24 hours.

Peers on Argus

CRON’s recent -3.09% move came as close peers were mixed: TLRY -1.19%, AKBA -4.0...
1 Up 1 Down

CRON’s recent -3.09% move came as close peers were mixed: TLRY -1.19%, AKBA -4.08%, and PCRX +2.29%. Momentum scanner names (HROW up 8.04%, BGM down 13.31%) also showed no unified direction, pointing to stock-specific dynamics rather than a sector-wide cannabis rotation.

Historical Context

5 past events · Latest: Dec 09 (Positive)
Pattern 5 events
Date Event Sentiment Move Catalyst
Dec 09 Netherlands acquisition Positive +8.9% Acquisition of CanAdelaar to secure leading share in Dutch adult-use pilot.
Nov 25 Product launch Positive +0.8% Launch of Lord Jones Live Resin Fusions pre-rolls in Canada.
Nov 06 Quarterly earnings Positive +0.8% Q3 2025 revenue growth, improved gross profit, and positive adjusted EBITDA.
Oct 28 Seasonal product launch Positive +0.8% Reintroduction of limited-edition Spinach Green Apple products for Fall 2025.
Oct 23 Earnings call notice Neutral +2.9% Announcement of scheduling for the 2025 Q3 earnings conference call.
Pattern Detected

Recent company news, including M&A, product launches, and earnings, has generally been followed by modestly positive next-day price reactions.

Recent Company History

Over the last few months, CRON has focused on international expansion and brand building. On Dec 9, 2025, it announced a CanAdelaar acquisition to enter the Netherlands, which saw an +8.91% reaction. Product launches under Spinach and Lord Jones in Canada and seasonal offerings in late 2025 all coincided with small positive moves. Q3 2025 results on Nov 6 highlighted growing revenue and liquidity, also met with a modestly positive response. Today’s Israel launch extends this borderless brand strategy into another key market.

Market Pulse Summary

This announcement advances Cronos’s borderless product strategy by introducing the premium Lord Jone...
Analysis

This announcement advances Cronos’s borderless product strategy by introducing the premium Lord Jones brand to Israel’s medical market with five indoor-grown flower strains. It builds on prior international and product expansion, including the Netherlands acquisition and Canadian launches. Key factors to monitor include patient uptake in Israel, pharmacy distribution breadth, and how this initiative contributes to revenue and margin trends highlighted in the company’s recent quarterly reports.

Key Terms

terpene, trichome
2 terms
terpene medical
"cold‑cure process designed to preserve terpene richness, aroma, trichome density"
Terpenes are natural aromatic compounds found in many plants and herbs that give them distinctive smells and flavors, similar to how spices give a dish its character. For investors, terpenes matter because they drive product differentiation, influence consumer preference, affect extraction and manufacturing costs, and can shape regulatory and medical claims—factors that impact revenue potential, margins, and supply-chain risk for companies in sectors like cannabis, flavors, fragrances, and wellness.
trichome medical
"designed to preserve terpene richness, aroma, trichome density, and overall flower structure"
Trichomes are tiny, hair-like glands on the surface of plants that produce and hold the plant’s active compounds, such as oils, resins and aromatic chemicals; on cannabis they contain the molecules that determine potency, flavor and medicinal effect. For investors, trichome development is a practical indicator of crop quality, harvest timing, lab-test results and regulatory compliance—think of them as the plant’s microscopic packing and quality-control units that directly influence product value and revenue potential.

AI-generated analysis. Not financial advice.

TORONTO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON; TSX: CRON) (“Cronos” or the “Company”), a leading global cannabinoid company, today announced the launch of its Lord Jones® premium cannabis brand in Israel. The introduction marks a significant milestone in Cronos’ borderless product strategy, expanding the Company’s globally recognized brand portfolio into one of the most advanced and discerning medical cannabis markets in the world.

The first phase of the launch brings five premium indoor-grown flower strains to Israeli patients. Lord Jones®, established in North America for its refined brand identity and elevated craftsmanship, now enters the Israeli medical market with a focus on meeting the needs of medical patients. The brand’s expansion into Israel underscores Cronos’ commitment to thoughtful international growth driven by disciplined execution and differentiated brand experiences.

“Israel has always represented a key market in our borderless product strategy,” said Mike Gorenstein, Chairman, President and CEO of Cronos. “By introducing Lord Jones® to Israeli patients, we are applying our global brand expertise to meet local demand while preserving the craftsmanship, quality standards, and premium identity, which have come to define Lord Jones®. This launch reflects our disciplined approach to international expansion and reinforces our commitment to building globally relevant cannabis brands anchored in quality and innovation.”

Lord Jones® cannabis flower is produced through a meticulous approach that begins with carefully selected genetics and continues through small batch indoor cultivation. Following harvest, the Lord Jones® cannabis products undergo a cold‑cure process designed to preserve terpene richness, aroma, trichome density, and overall flower structure. Each batch is hand‑trimmed, produced in limited quantities, and tested extensively to meet rigorous standards. To maintain freshness and protect terpene profiles over time, the finished product is hand packaged in glass jars, which helps shield the flower from light exposure and preserve its quality.

“The launch of the Lord Jones® brand in Israel marks an important milestone for us, bringing a premium standard to the Israeli medical market, which is grounded in expertise and intention,” said Adam Wagner, General Manager of Cronos Israel. “Every stage of our work is guided by rigorous oversight and meticulous processes, from genetics and cultivation through meticulous processing and hand packaging. This end-to-end approach gives patients and pharmacists confidence in the standards behind the brand, delivering a premium defined by transparency and an unwavering commitment to quality.”

In addition to the core flower offering, Cronos plans to expand the Lord Jones® brand in Israel with future special edition and limited‑run products. Lord Jones® products are now available in pharmacies across Israel.

About Cronos Group Inc. 
Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com. 
 
Forward-looking Statements  
This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, “Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about the Company’s borderless product strategy, international growth and expansion, expectations regarding market trends, consumer preferences, pricing dynamics; demand for premium cannabis products; the anticipated benefits of the launch of the Lord Jones® brand in Israel; future Lord Jones® product offerings in Israel; and the Company’s intention to build an international iconic brand portfolio and develop disruptive intellectual property by advancing cannabis research, technology and product development. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, each of which have been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement. 
 
For further information, please contact:  
 
Media Relations Contact:
Emily Whalen  
Communications  
Tel: (416) 504-0004  
media.relations@thecronosgroup.com   
 
Investor Relations Contact:
Harrison Aaron  
Investor Relations  
Tel: (416) 504-0004  
investor.relations@thecronosgroup.com  


FAQ

What did Cronos Group (CRON) announce about Lord Jones in Israel on February 2, 2026?

Cronos announced the launch of Lord Jones with five premium indoor-grown flower strains for Israeli medical patients. According to the company, the rollout emphasizes small-batch cultivation, cold-cure processing, hand trimming and glass jar packaging to preserve terpene profiles and quality.

Which Lord Jones product types are available now in Israel from Cronos (CRON)?

Lord Jones flower is currently available in pharmacies across Israel, starting with five indoor-grown strains. According to the company, the initial offering focuses on core premium flower with plans for future special edition and limited-run products.

How does Cronos (CRON) describe Lord Jones cultivation and processing standards in Israel?

Cronos describes Lord Jones cultivation as small-batch indoor with cold-cure processing and hand trimming to protect terpenes and structure. According to the company, finished product is hand packaged in glass jars to preserve freshness and terpene profiles over time.

Why is the Lord Jones launch in Israel important to Cronos Group (CRON)?

The launch advances Cronos' borderless product strategy by entering a sophisticated medical cannabis market. According to the company, it demonstrates disciplined international expansion and applies global brand expertise to meet local patient and pharmacist needs.

Will Cronos (CRON) expand Lord Jones offerings in Israel beyond the initial launch?

Yes, Cronos plans to expand Lord Jones in Israel with future special edition and limited-run products. According to the company, these additions will follow the same small-batch, high-quality processes and aim to broaden patient choice over time.
Cronos Group

NASDAQ:CRON

CRON Rankings

CRON Latest News

CRON Latest SEC Filings

CRON Stock Data

1.00B
197.78M
47.07%
14.7%
0.68%
Drug Manufacturers - Specialty & Generic
Medicinal Chemicals & Botanical Products
Link
Canada
STAYNER